Aura Biosciences SVP sells 1,581 AURA shares

Amy Elazzouzi, Senior Vice President, Finance of Aura Biosciences, Inc. (AURA), reported an insider transaction involving company common stock.

Rhea-AI Filing Summary

Amy Elazzouzi, Senior Vice President, Finance of Aura Biosciences, Inc. (AURA), reported an insider transaction involving company common stock. On January 20, 2026, she sold 1,581 shares of common stock at $4.86 per share. According to the disclosure, these shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units, and the sales were automatic rather than discretionary. After this transaction, she beneficially owned 84,081 shares of Aura Biosciences common stock, held directly.

Insider Trade Summary

Net Seller: 1,581 shares

Net Sell 1 txn

Insider Elazzouzi Amy

Role Senior Vice President, Finance

Sold 1,581 shs ($8K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,581	$4.86	$8K

Holdings After Transaction: Common Stock — 84,081 shares (Direct)

Footnotes (1)

1. F1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AURA executive Amy Elazzouzi report?

Amy Elazzouzi, Senior Vice President, Finance of Aura Biosciences, reported the sale of 1,581 shares of AURA common stock on January 20, 2026 at a price of $4.86 per share.

Why did Amy Elazzouzi sell Aura Biosciences (AURA) shares?

The filing states that the reported sales were made to cover tax withholding obligations in connection with the vesting of restricted stock units, and that the sales were automatic and not at her discretion.

How many Aura Biosciences (AURA) shares does Amy Elazzouzi own after the transaction?

Following the reported sale, Amy Elazzouzi beneficially owned 84,081 shares of Aura Biosciences common stock, held in direct ownership.

What role does Amy Elazzouzi hold at Aura Biosciences (AURA)?

Amy Elazzouzi serves as Senior Vice President, Finance at Aura Biosciences, Inc., and filed this Form 4 as an officer of the company.

Was the Aura Biosciences (AURA) insider sale part of a discretionary trading decision?

No. The footnote explains that the sale represented shares required to be sold to cover tax withholding on restricted stock unit vesting and that these sales were automatic, not made at the reporting person’s discretion.

What type of security was involved in the AURA Form 4 transaction?

The Form 4 transaction involved common stock of Aura Biosciences, Inc., with 1,581 shares sold at $4.86 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/20/2026 - 06:41 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Elazzouzi Amy

(Last) (First) (Middle)

C/O AURA BIOSCIENCES, INC.

80 GUEST STREET

(Street)

BOSTON MA 02135

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aura Biosciences, Inc. [ AURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior Vice President, Finance

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		S(1)		1,581	D	$4.86	84,081	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

	/s/ Amy Elazzouzi	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.